Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: long-term results from COSMOS

BACKGROUND: While immediate benefits of levodopa–carbidopa intestinal gel (LCIG) are evident in patients with Parkinson’s disease (PD), long-term LCIG effects require further study. OBJECTIVES: We explored long-term LCIG on motor symptoms, nonmotor symptoms (NMS), and LCIG treatment settings in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Fasano, Alfonso, García-Ramos, Rocío, Gurevich, Tanya, Jech, Robert, Bergmann, Lars, Sanchez-Soliño, Olga, Parra, Juan Carlos, Simu, Mihaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130122/
https://www.ncbi.nlm.nih.gov/pubmed/36802031
http://dx.doi.org/10.1007/s00415-023-11615-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130122/
https://www.ncbi.nlm.nih.gov/pubmed/36802031
http://dx.doi.org/10.1007/s00415-023-11615-3

Ejemplares similares